Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intravascular Ultrasound for Hepatocellular Carcinoma Staging

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2007 by University Hospital, Geneva.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT00474734
First received: May 15, 2007
Last updated: May 16, 2007
Last verified: May 2007

May 15, 2007
May 16, 2007
May 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00474734 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Intravascular Ultrasound for Hepatocellular Carcinoma Staging
Intravascular Ultrasound for the Staging of Hepatocellular Carcinoma: a Pilot Study

To diagnose hepatocellular carcinoma (HCC) and to determine the extent of the disease, a triphasic CT scan or a magnetic resonance imaging are required. The characterization of hepatic nodules is more difficult when the HCC lesions have a diameter of less than 2 cm.

Since accuracy in the assessment of the number and the size of HCC nodules, as well as of the invasion of blood vessels is crucial to determine outcome after liver transplantation due to tumour recurrence, there is a need for techniques with a higher definition potential.

As a consequence, to improve outcome and to optimize organ allocation, patients on the liver transplantation waiting list might benefit from intravascular ultrasound as an additional examination to complete the pre-transplant tumour staging process.

Not Provided
Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
Hepatocellular Carcinoma
Device: Intravascular ultrasound of the liver
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
Not Provided
September 2007
Not Provided

Inclusion Criteria:

  • hepatocellular carcinoma nodules
  • patient on liver transplantation waiting list
  • written informed consent

Exclusion Criteria:

  • thrombosis of hepatic veins or vena cava
Both
18 Years to 65 Years
No
Contact: Antoine Hadengue, Prof. +41 22 37 29 340 antoine.hadengue@hcuge.ch
Switzerland
 
NCT00474734
07-063
Yes
Not Provided
University Hospital, Geneva
Not Provided
Study Chair: Antoine Hadengue, Prof. University Hospital, Geneva
University Hospital, Geneva
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP